Please use this identifier to cite or link to this item:
Title: Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
Authors: Cunningham, Anthony L.
Heineman, Thomas C.
Lal, Himal
Godeaux, Olivier
Chlibek, Roman
Hwang, Shinn-Jang
McElhaney, Janet E.
Vesikari, Timo
Andrews, Charles
Choi, Won Suk
Esen, Meral
Ikematsu, Hideyuki
Choma, Martina Kovac
Pauksens, Karlis
Ravault, Stephanie
Salaun, Bruno
Schwarz, Tino F.
Smetana, Jan
Vanden Abeele, Carline
Van den Steen, Peter
Vastiau, Ilse
Weckx, Lily Yin [UNIFESP]
Levin, Myron J.
Keywords: varicella-zoster virus
herpes zoster vaccine
gE subunit vaccine
adjuvant system
Issue Date: 2018
Publisher: Oxford Univ Press Inc
Citation: Journal Of Infectious Diseases. Cary, v. 217, n. 11, p. 1750-1760, 2018.
Abstract: Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01(B) Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: >= 50
ZOE-70: >= 70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing >= 2 of 4 activation markers assessed (CD4(2+)) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD4(2+) T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained >= 5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination.
ISSN: 0022-1899
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
File SizeFormat 
WOS000434081100009.pdf2.97 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.